Jasper Therapeutics Inc (JSPR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.61 (-3.85%), Market cap $0.02B, 52-week low–high $0.67 ~ $6.82.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Financial statements, price targets, institutional (13F) holdings and related news for Jasper Therapeutics Inc are updated in real time on BlackAll Trade.
Jasper Therapeutics Inc trades at $0.61 (-3.85%). Real-time quotes and charts are available on BlackAll Trade.
Jasper Therapeutics Inc has a market cap of about $0.02B.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidat